ArticleIntestinal Failure (New York, N.Y.)
Alpha1-antitrypsin protects the intestine from ischemia-reperfusion injury in a rat intestinal clamping model.
Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated Gut-Brain Axis Response to Freezing and Recovery in Freeze-Tolerant Fish,Animals : an open access journal from MDPI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemia-reperfusion injury (IRI) remains a significant hurdle when blood flow is restored to ischemic tissue. Alpha1-antitrypsin (AAT), a serine protease inhibitor, has demonstrated strong anti-inflammatory properties, including inhibition of neutrophil recruitment and activation. In this study we aim to investigate its potential to mitigate intestinal IRI (IIRI). Material and Methods: The experimental protocol included two phases, performed in male Sprague-Dawley rats (250-350 g). Intravenous treatment was administered 10 min before ischemia induced by 60 min of superior mesenteric artery clamping. In the first phase, groups (N = 7/group) were: sham (PBS), AAT/60 (AAT60mg/kg+IRI), and AAT/100 (AAT100mg/kg+IRI), with 7-day survival as primary endpoint. Selecting AAT dose based on Phase 1 results, Phase 2 included three groups (N = 6/group): sham (PBS), control (PBS+IRI), and AAT (AAT+IRI). Reperfusion lasted 60 min, followed by animals sacrifice for sampling. Endpoints were transepithelial electrical resistance (TEER, villus length-adjusted), histological injury (Park-Chiu score), neutrophil infiltration (MPO immunohistochemistry), ileal cytokine levels (IL-6,IL-10,IL-1β,TNFα), and arterial blood analysis (blood gas, endotoxin, IL-6). Results: In phase 1, AAT/60 Conclusion: By modulating neutrophil activity, AAT appears to reduce IIRI local/systemic effects, leading to improved 7-day survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.